Notch Antibody Proves Metastatic Lung Cancer Has a Jagged Edge

We at Novus Biologicals are one of the leading antibody suppliers for cancer research. In a recent Notch antibody study, the Notch ligand Jagged 2 was found to promote the growth of metastatic lung cancer cells by inhibiting miR-200, which blocks epithelial-to-mesenchymal transition (EMT) – an early stage in metastasis which, if blocked, can prevent secondary tumour growth.

The Notch proteins are large single-pass transmembrane receptors, important to embryonic development cell signalling. It comprises an intracellular and extracellular domain, the latter being composed of EGF-like repeats and cysteine-rich Notch/Lin-12 repeats. Notch signalling is initiated following Delta or Jagged1/2 ligand binding. Antibody studies have shown this results in cleavage of the extracellular domain, initiating translocation of the intracellular fragment to the nucleus, triggering transcription of various genes.

The Notch proteins have a large number of positive and negative regulators, which work by binding the ankyrin repeat region of the intracellular domain. Notch antibody studies have shown the promoter binding factor CBF1 is bound at the ankyrin repeat and RAM domain. The Notch/CBF1 complex is able to affect access the genome to activate transcription via histone acetylase/deacetylase activity.

In the recent study, Yang et al used Jagged2, GAT and Notch antibody products to investigate the role of Notch in lung tumour metastasis, using a mouse model. They discovered Notch2 controls expression of GATA3, a protein which works in counter-inhibitory fashion with the microRNA miR-200. In knock-down studies, suppression of Jagged2 or overexpression of GATA3 led to increased levels of miR-200, preventing metastasis from occurring.

Novus Biologicals offers many Notch reagents for your research needs including:

• Notch Antibodies
• Notch Lysates
• Notch RNAi
• Notch ELISA Kits
• Notch Peptides and Proteins